Plain-English translation of NCT04161495 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested , a new intravenous medication designed to help blood clot in people with severe hemophilia A. Participants received either weekly preventive injections for a full year, or as-needed injections for six months followed by weekly preventive treatment for another six months. The study examined how safe and effective this medication was and how the body processed it over time.
People with severe hemophilia A struggle with spontaneous bleeding and need frequent treatment. This trial was designed to see if this new medication could provide better, longer-lasting protection and require fewer injections than existing treatments.
Participants were assigned to one of two groups. Some received weekly intravenous injections of the medication for 52 weeks. Others started with as-needed injections (when a bleeding episode occurred) for the first 26 weeks, then switched to weekly preventive injections for the remaining 26 weeks. Participants tracked their bleeding episodes and medication use in an electronic diary throughout the study.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
United States